May 25-27

This article is from the Guangzhou Huangpu District People's Government portal website Sun Xudong Fan Minling Zhou Yadong

The first Guangzhou International Biomedical Industry Conference was held in Huangpu. The picture shows Academician Zhao Yuliang making a keynote report.

Huangpu District Guangzhou Development Zone 12 high-quality biopharmaceutical projects signed.

From May 25 to 27, the first Guangzhou International Biomedical Industry Conference was held in Huangpu for three days. Qu Fenghong, Vice president of the Chinese Pharmaceutical Society, Zhang Xinmin, director of the China Biotechnology Development Center, Wei Yuquan, Academician of the Chinese Academy of Sciences, Zhao Yuliang, academician of the Chinese Academy of Sciences and other 10 scientists from a number of research institutes at home and abroad attended the opening ceremony held on the 26th. Nearly 1,000 representatives of well-known enterprises and institutions in the field of biomedicine attended the opening ceremony.

The conference highlights the theme of "industry" and focuses on 11 hot topics such as new biomedical infrastructure, new molecular drug research and development, cellular drug development, innovative drug commercialization, gene editing and gene therapy, clinical research and development, and tumor vaccines. Twelve high-quality biomedical projects were signed at the meeting, and 14 industry leaders were hired as consultants for the development of Guangzhou (Whampoa) biomedical industry. For the current Guangdong-Hong Kong-Macao Greater Bay Area drug and medical device industry concerned policy "Hong Kong and Macao drug and equipment", this event also set up a special seminar salon.

Prominent advantages: Huangpu to create the biological industry investment choice

As the key town of Guangzhou's biomedical industry, Huangpu District and Guangzhou Development Zone have always taken the biomedical industry as the top priority in the development of manufacturing industry. At present, the region has gathered more than 3,000 biomedical enterprises, and the revenue scale of the biomedical and health industry has exceeded 200 billion yuan, creating an industrial chain pattern of "research and development in the biological island, pilot test in the science city, and manufacturing in the knowledge city".

Compared with other domestic biopharmaceutical industrial clusters, Huangpu District and Guangzhou Development Zone have formed two prominent advantages: first, capacity advantage, the production scale of macromolecular biopharmaceutical liquid under construction exceeds 600,000 liters; The second is the number of advantages, the number of innovative drugs in the national development zones in the forefront.

A number of experts and entrepreneur representatives at the meeting said that the Guangdong-Hong Kong-Macao Greater Bay Area biological industry has prominent advantages and broad market prospects, and Huangpu District, as the core area for the development of the biological industry in the Greater Bay Area, has now become one of the preferred places for biomedical enterprises to invest and settle down.

The Guangzhou Weske Vaccine research and development and production project of Academician Wei Yuquan's team is a key project signed by Huangpu District and Guangzhou Development Zone in the past two years. On May 17, the recombinant multivalent novel coronavirus protein vaccine developed by Wesker Biological/Sichuan University West China Hospital for the latest popular XBB and other COVID-19 variants was approved by the State Food and Drug Administration for clinical trials, which is also the first COVID-19 vaccine against XBB and other variants to enter clinical trials in the world. Academician Wei Yuquan said at the meeting, "In the future, Wesker Bio will continue to deeply cultivate Huangpu, transform the latest and best results in Huangpu District, achieve industrialization, and jointly promote the high-quality development of Guangzhou and Huangpu biomedical industry."

Malcolm Ritchson, Fellow of the Royal College of Pathologists and the Royal Society of Biology, also said in the keynote report: "With the strong support of the Guangzhou Development Zone, Ritchson Medical has built the first third-party independent medical laboratory of medical fungi in China in Guangzhou International Biological Island, which has achieved sustainable development."

Jean Paul Thiery, Honorary scientist of the French National Academy of Sciences, Chief Scientist and Chairman of the Scientific Committee of Bagel Biosciences, also introduced in the keynote speech that Singapore Bagel Biosciences, as the first biopharmaceutical company to enter the Sino-Singapore Guangzhou Knowledge City in 2016, focuses on the development of innovative immune cell therapies that are the first in the world. "The excellent investment environment, efficient and advanced management concepts and means of Knowledge City give Baiji Biology a strong sense of belonging, security and gain."

At this conference, 12 high-quality biomedical projects were signed, including foreign-funded projects such as TEVA Pharmaceutical's (TEVA) China Innovative drug transformation Base, canmerry Innovative medical Device R&D and Production Center project (CPI), and Dongfulong Life Science equipment R&D headquarters and other headquarters projects. As well as Hui Zhengqi mRNA innovative drug research and development headquarters, Mai Jinjia nucleic acid drug research and development center, Xinxiang International biomedical Industrial Park and other research and development centers and supporting projects.

"In addition to having an industrial environment suitable for the development of biopharmaceutical enterprises, Huangpu has a series of supporting resources to assist enterprises in an all-round way." The most attractive reason for me to come here is that I can actually feel the government services." Hui Zhengqi founder Hui Aimin said. Zhang Jianchun, chairman of Guangzhou Hengnuokang Pharmaceutical Technology Co., LTD., also said that biomedical companies need to innovate continuously, but there is inevitably a risk of failure in the process of innovation, and Huangpu District has given great support in all aspects to do practical things for enterprises.

"Think tank" suggestions: open up the industry communication barriers

Biomedical industry projects have invested in Huangpu, and industry talents are also gathering in Huangpu. At the event, 14 leading figures in the biomedical industry from scientific research institutions, medical institutions and Situfan, Lonza, Astrazeneca, Beigene, Hengrui, Kangfang and Luye were hired as consultants for the development of the biomedical industry in Guangzhou (Whampoa).

It is understood that the next Huangpu District will form a biomedical industry "think tank" through industrial consultants in different links of the industrial chain, give full play to resource advantages, open up the communication barriers between government departments, scientific research institutions, medical institutions and innovative drugs, in vitro diagnosis, medical devices and other enterprises, realize the full docking of "government, production, university and research", and enhance the endogenous power of the biomedical industry chain supply chain. We will promote the high-quality development of the biomedical industry.

Previously, Huangpu District has established a system to introduce Zhong Nanshan, Zhao Yuliang, Xu Tao, Wang Xiaodong and other academician teams, gathering more than 50 high-end life science talents, 507 national, provincial and municipal high-level talents in the field of biomedicine, and initially forming three strong teams of strategic scientists, excellent clinicians and excellent entrepreneurs, creating a strong potential energy of "going to Huangpu".

Knowledge promotes industry and talents promote development. The employment of industry consultants will further tighten the "talent circle" of Huangpu District's biomedical industry, and turn the "social circle" of close communication into the "ecological circle" of cutting-edge innovation.

Radiation Bay Area: Hui enterprise initiative to bring forth the new

Behind the industrial advantage is the policy advantage. In recent years, Huangpu District and Guangzhou Development Zone have successively launched a series of industrial policies such as "8 high-end biopharmaceuticals" and "10 biopharmaceuticals". On May 22 this year, Huangpu District issued the "30 high-quality development", vigorously supporting the strategic emerging industries represented by biomedicine, and supporting key enterprises up to 100 million yuan.

Location advantage is one of the key words in Huangpu District's new measures to benefit enterprises. As the core area of the biomedicine industry in the Guangdong-Hong Kong-Macao Greater Bay Area, the innovation policy of Huangpu District has continued to increase, and various pilot policies such as the Hong Kong and Macao Drug and Equipment connection and simplified approval of Hong Kong and Macao proprietary Chinese medicines for external use have been implemented in the district, speeding up the inclusion of innovative pharmaceutical devices in medical insurance, collection, network deployment, and admission.

Among them, the "Hong Kong and Macao Drug and Equipment Connect" allows clinically urgent drugs that have been listed in Hong Kong and Macao, as well as clinically urgent medical devices that have been purchased and used by public hospitals in Hong Kong and Macao and have advanced clinical application to be used by qualified medical institutions in the Mainland of the Guangdong-Hong Kong-Macao Greater Bay Area after approval. As of April 3, 2023, the policy has approved a total of 19 designated medical institutions, 23 urgently needed imported drugs, and 13 medical devices.

The new policy has been implemented, how to make the innovative measures benefit a wider range? The event set up a special salon of "Hong Kong and Macao Medicine and Equipment", and representatives from the Guangdong Provincial Health Commission, the Food and Drug Administration and relevant medical institutions, biopharmaceutical and medical device enterprises exchanged views and also put forward application needs. Teva Pharmaceuticals, one of the signatories at the opening ceremony, will take the lead in introducing drugs that have been approved for listing in Hong Kong to Guangzhou through the Greater Bay Area's "Hong Kong and Macao Drug and Equipment" policy in the future, and gradually introduce the group's various innovative drugs, biosimilar drugs, small molecule generic drugs and over-the-counter drug pipelines according to the demand of the Chinese market.